FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
News|Articles|April 1, 2026
5 FDA Decisions for Primary Care to Know from March 2026
Author(s)Sydney Jennings
From new oral options for for psoriatic disease to once-weekly insulin, 5 FDA decisions with implications for primary care practice.
Advertisement
Advertisement
In March, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning immunology,
Related to this article
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Advertisement
Advertisement